Corinne Johnson Maintained (avbp) at Strong Buy with Increased Target to $38 on, Sep 10th, 2024
Corinne Johnson of Goldman Sachs, Maintained "ArriVent BioPharma, Inc." (AVBP) at Strong Buy with Increased Target from $28 to $38 on, Sep 10th, 2024.
Corinne, nor any peers, have made any analyst calls on AVBP in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources